Division of Hematology/Oncology, Department of Medicine, Tulane Cancer Center, New Orleans, Louisiana, USA.
Curr Opin Urol. 2012 May;22(3):183-9. doi: 10.1097/MOU.0b013e32835259d2.
Randomized clinical trials of palliative radiation therapy and radiopharmaceuticals are emphasized, and new concepts in targeted alpha-emitter therapy are introduced.
Radiation therapy has a proven palliative role in the treatment of patients with advanced prostate cancer. Findings from 223radium clinical trials emphasize the importance of alpha particles as a new therapeutic modality in patients with bone metastatic castrate-resistant prostate cancer. We introduce the concept of alpha-emitting particles from both a basic and clinical perspective in the realm of bone-targeted radiopharmaceuticals and discuss how these agents compare and contrast with conventional beta-emitting radioisotopes. The physics, radiobiology, and survival data with 223radium are unique compared with previously used radiopharmaceuticals.
Targeted alpha-emitting therapies such as 223radium have the capacity to change the way we treat patients with bone-metastatic prostate cancer.
强调姑息性放射治疗和放射性药物的随机临床试验，并介绍靶向 α 放射疗法的新概念。
放射治疗在治疗晚期前列腺癌患者方面具有明确的姑息作用。223 镭临床试验的结果强调了α粒子作为一种新的治疗方式在患有骨转移去势抵抗性前列腺癌患者中的重要性。我们从基础和临床两个方面介绍了骨靶向放射性药物中 α 发射粒子的概念，并讨论了这些药物与传统的 β 发射放射性同位素相比如何进行比较和对比。与以前使用的放射性药物相比，223 镭的物理、放射生物学和生存数据是独特的。
靶向 α 放射疗法，如 223 镭，有可能改变我们治疗骨转移前列腺癌患者的方式。
Zotero 插件